538 related articles for article (PubMed ID: 21572312)
1. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls.
Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE
Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312
[TBL] [Abstract][Full Text] [Related]
2. Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin.
Paner GP; Lopez-Beltran A; Sirohi D; Amin MB
Adv Anat Pathol; 2016 Mar; 23(2):71-83. PubMed ID: 26849813
[TBL] [Abstract][Full Text] [Related]
3. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
5. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
6. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
[TBL] [Abstract][Full Text] [Related]
7. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
10. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms.
Kermanshahi TR; Jayachandran P; Chang DT; Pai R
Appl Immunohistochem Mol Morphol; 2014; 22(10):728-34. PubMed ID: 25394300
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.
Sullivan LM; Smolkin ME; Frierson HF; Galgano MT
Am J Surg Pathol; 2008 Nov; 32(11):1608-12. PubMed ID: 18753946
[TBL] [Abstract][Full Text] [Related]
12. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
[TBL] [Abstract][Full Text] [Related]
13. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
Groisman GM; Meir A; Sabo E
Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
[TBL] [Abstract][Full Text] [Related]
14. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
Riva G; Mian C; Luchini C; Girolami I; Ghimenton C; Cima L; Novelli L; Hanspeter E; Mazzoleni G; Schwienbacher C; Pycha S; D'Elia C; Trenti E; Pycha A; Martignoni G; Hes O; Eccher A; Nesi G; Brunelli M
Virchows Arch; 2019 Jan; 474(1):13-20. PubMed ID: 30302546
[TBL] [Abstract][Full Text] [Related]
15. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
Oliva E; Amin MB; Jimenez R; Young RH
Am J Surg Pathol; 2002 Feb; 26(2):190-7. PubMed ID: 11812940
[TBL] [Abstract][Full Text] [Related]
16. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
17. Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel.
Tamboli P; Mohsin SK; Hailemariam S; Amin MB
Arch Pathol Lab Med; 2002 Sep; 126(9):1057-63. PubMed ID: 12204054
[TBL] [Abstract][Full Text] [Related]
18. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
Park KJ; Bramlage MP; Ellenson LH; Pirog EC
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):8-11. PubMed ID: 18776815
[TBL] [Abstract][Full Text] [Related]
19. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
20. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma.
Saad RS; Silverman JF; Khalifa MA; Rowsell C
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):196-201. PubMed ID: 19098678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
